Evidence map›Paper›PMID 42676291›Full record

ArticleThe journal of pathology. Clinical research2026

Artificial intelligence-assisted histopathological diagnosis of endocervical gastric-type adenocarcinoma: a multicenter model development and validation study.

Jing Yang, Qiming He, Jing Peng, Yizhi Wang, Jiawen Li, Haoxiang Li, Yan Liu, Yuxiang Wang, Ajin Hu, Xitong Ling and 15 more

Abstract readMulticenter StudyValidation Study
In one paragraph

Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Jing Yang *Department of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China.ORCID https://orcid.org/0009-0009-1574-4428
Qiming He *Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Jing Peng *Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Yizhi WangInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Jiawen LiInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.ORCID https://orcid.org/0000-0001-9339-2557
Haoxiang LiDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China.
Yan LiuDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China.
Yuxiang WangDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China.
Ajin HuDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China.ORCID https://orcid.org/0000-0003-4081-3076
Xitong LingInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.ORCID https://orcid.org/0009-0008-2016-5255
Yingwen ZhangInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Minxi OuyangInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Xinrui ChenInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Lianghui ZhuInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Yiqing LiuInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Yexing ZhangJinan Inspur Data Technology Co., Ltd., Jinan, PR China.
Siqi ZengInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Qiang HuangInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Zihan WangInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Tian GuanInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Yueping LiuDepartment of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, PR China.
Ling ChenDepartment of Pathology, Tianjin Institute of Gynaecology Obstetrics, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, PR China.ORCID https://orcid.org/0000-0003-3128-3472
Yan DingDepartment of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, PR China.
Yonghong HeInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, PR China.
Congrong LiuDepartment of Pathology, Peking University Third Hospital, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China.ORCID https://orcid.org/0000-0002-9876-1603

Funding

Fuzhou University Research Start-up Grant for Introduced Talents XRC-25119Government-funded Training Program for Outstanding Clinical Medicine Talents ZF2023045Key Clinical Projects of Peking University Third Hospital BYSYDL2025003National Key Research and Development Program of China 2023YFC270580-5National Natural Science Foundation of China 81500475National Natural Science Foundation of China 82430062National Natural Science Foundation of China 82473150Shenzhen Engineering Research Centre XMHT20230115004Tianjin Natural Science Foundation Project 23JCYBJC01850Tsinghua Shenzhen International Graduate School Cross-disciplinary Research and Innovation Fund Research Plan JC2024002
6 · The paper itself

Abstract

Endocervical gastric-type adenocarcinoma (GAS) is one of the most aggressive subtypes of cervical cancer and is frequently underdiagnosed due to morphological ambiguity, leading to delayed diagnosis. Despite the availability of molecular and genomic assays, their high cost, complexity, and limited reproducibility restrict clinical use. This study therefore proposes a highly sensitive artificial intelligence (AI)-assisted diagnostic system for GAS based exclusively on H&E-stained histopathological images. We included 309 slides from 96 GAS cases collected at Peking University Third Hospital from January 2018 to January 2025, representing the largest GAS cohort reported to date for AI research. In addition, we incorporated other morphologically analogous diseases, encompassing a total of 1,320 slides sourced from four categories: normal cervical mucosa (NORM), benign endocervical lesion entities (BELE), HPV-associated adenocarcinoma (HPVA), and endometrioid carcinoma with mucinous differentiation (ECMD). We developed GASPath, based on a novel multiple instance learning framework that efficiently captures fine-grained morphological variations from H&E-stained images. Beyond internal validation, GASPath was evaluated across 12 independent retrospective cohorts and further subjected to large-scale real-world validation on more than 7,000 samples from March 2024 to April 2025. Across three stages, GASPath demonstrated high performance. In internal validation (Stage I), it achieved an accuracy of 0.980 (95% CI 0.977-0.983) and an ROC-AUC of 0.995 (95% CI 0.994-0.997). In external validation (Stage II), the sensitivity reached 0.902 and improved to 0.968 with proposed strategies. For biopsy samples, GASPath achieved an ROC-AUC of 0.990 (95% CI 0.984-0.997). In large-scale real-world deployment (Stage III, n = 7,056), GASPath achieved a balanced accuracy of 0.953, with 100% sensitivity for GAS (45/45 cases correctly identified). The heatmaps highlight morphological features of GAS that are easily underestimated, such as irregular, angulated glands, subtle loss of nuclear polarity, and mild cytologic atypia, which show substantial morphological overlap with other diagnostic categories. GASPath enables high-sensitivity detection of GAS in routine H&E-stained slides, obviating the need for extensive auxiliary testing while preventing underdiagnosis and misdiagnosis. This advancement addresses a critical gap by streamlining diagnostic workflows without compromising accuracy. Its implementation could enable cost-effective, scalable AI-assisted diagnostics, potentially transforming the early detection and management of this aggressive cancer subtype.

Indexed as

AdenocarcinomaArtificial IntelligenceDiagnosis, Computer-AssistedImage Interpretation, Computer-AssistedUterine Cervical NeoplasmsAdultFemaleHumansMiddle AgedMultiple-Instance Learning AlgorithmsPredictive Value of TestsReproducibility of ResultsRetrospective Studiesartificial intelligence (AI)diagnosisendocervical gastric‐type adenocarcinoma (GAS)H&E‐stained slideshistopathologymulticenter studymultiple instance learning (MIL)

Identifiers

PMID42676291
PMCPMC13531234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.